Showing data about arrow_drop_down
Update
- The pharma industry - R&D
- The pharma industry in figures - Economy
- The pharma industry in figures - Employment
- The pharma industry in figures - Healthcare
- Value to patients
- Value to healthcare systems
- Value to the economy
- Value to society
- Medicines cost in context
- Pharmaceutical R&D expenditure in Europe, USA and Japan
- R&D process
- R&D in Europe
- Allocation of R&D investments
- New chemical or biological entities
- Estimated costs of bringing a new entity to market
- Pharmaceutical R&D expenditure - Annual growth rate (%)
- R&D intensity
- Impact on the European economy
- Geographical breakdown of sales of new medicines
- R&D expenditure in Europe, USA and Japan
- Parallel imports
- Production
- World pharmaceutical market
- Market value
- VAT rates
- Generics
- Imports and exports
- Trade balance (by country)
- Trade balance - high technology sectors
- EU main pharmaceutical trading partners
- Employment in the pharmaceutical industry (by country)
- Employment in the pharmaceutical industry (by year)
- Employment in pharmaceutical R&D
- Total spending on healthcare
- Payment for pharmaceuticals
- Causes of death by major disease areas
- Breakdown of health expenditure
- New medicines
- Cancer mortality
- Cancer - life expectancy
- Hep C - cure rates
- Chronic diseases - impact
- Vaccines - impact
- HIV - death rates
- Innovation
- Personalised medicines - Leukemia survival
- Personalised medicines - Lung cancer
- Rare diseases
- Medicines benefits
- Health gains and savings
- The added value of medicines
- Shift towards cure and prevention
- Medicines and total healthcare costs
- Industry contribution to European economy
- R&D spending by industry
- R&D spending as a percentage of net sales
- Value added per employee
- Worldwide pharmaceutical R&D investment
- UK pharmaceutical R&D investment
- Innovative treatments – longevity and productivity of patients
- Clinical Trials
- Unmet medical needs
- Cancer survivorship and employment
- Healthcare systems – challenges
- Ageing population
- Chronic disease
- Pharmaceutical expenditure
- Pharmaceutical expenditure in Germany
- Cancer-related healthcare costs
- Cost-reduction of off-patent medicines
- Generic medicines
- Biosimilars
- Health outcomes
Industry development and subsequent approvals have historically been targeting major unmet medical need
Source: Health and growth (2013-2014) based on Catala-Lopez 2010 Does the development of new medicinal products in the European Union address global and regional health concerns? Pop Health Met.
Source: Health and growth (2013-2014) based on Catala-Lopez 2010 Does the development of new medicinal products in the European Union address global and regional health concerns? Pop Health Met.